Navigation Links
United States Market for Psoriatic Arthritis Pharmacotherapy

NEW YORK, July 10, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

United States Market for Psoriatic Arthritis Pharmacotherapy

This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as well as the background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).

Executive Summary•The market for psoriatic arthritis (PsA) pharmacotherapeutics is currently comprised of a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for anti-TNF refractory patients represents a significant unmet need.•Revenue generated from sales of TNF inhibitors for PsA in the United States was approximately $xxx.x million in 2011 and dominated by Amgen. Revenue for the PsA therapeutic area is expected to increase to approximately $x,xxx.x million in 2017, aided by the addition of several new therapies to the market.•Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17 (IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.•Development of therapies for this complex disease and market penetration is hindered by several factors including a perception of PsA as a milder disease compared to rheumatoid arthritis (RA), and incompletely understood pathogenesis.•Although some therapies such as TNF inhibitors that are effective for the treatment of RA are also effective for PsA, this is not always the case due to differences between the two diseases.•Accumulating evidence supporting the importance of prompt initiation of effective disease modifying therapy for better long-term outcomes for patients with PsA is driving development of novel therapies aimed at improving symptoms and slowing disease progression.•Estimates of the prevalence of PsA vary widely, but it is generally considered to occur in approximately xx to xx percent of psoriasis sufferers, or approximately xxx,xxx to x.x million men and women in the United States.•Diagnostic difficulties are thought to result in unawareness of the condition by many patients and significant under-treatment.


Executive Summary 4

Market Overview 10

Psoriatic Arthritis Pharmacotherapeutics Market -

External Challenges: Drivers and Restraints 20

Forecast and Trends 30

Demand Analysis 41

Market Share and Competitive Analysis 44

TNF Inhibitor Segment Breakdown 54

Non-TNF Biologics Segment Breakdown 65

Novel Oral DMARDs Segment Breakdown 73

The Last Word 81

Appendix 86

To order this report: Pathology Industry: United States Market for Psoriatic Arthritis Pharmacotherapy 

More  Market Research Report Check our  Industry Analysis and Insights

Nicolas Bombourg Reportlinker Email: US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United States Surgical Equipment Market Outlook to 2018- Electrosurgical Devices, Hand Instruments and Surgical Sutures
2. United Kingdom ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
3. Zimmer Introduces First Porous Metal Interbody Implant for Lumbar Spine in the United States
4. United States ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
5. United Spinal To "Roll on Capitol Hill:" Voices Aim to Impact Federal Health Care Policy
6. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
7. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
10. Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
11. Analysis of the North American Radiology Image and Information Management Systems Market
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology:
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):